No Data
Analysts Are Updating Their Caribou Biosciences, Inc. (NASDAQ:CRBU) Estimates After Its Third-Quarter Results
Caribou Biosciences' Strategic Advancements and Financial Efficiency Bolster Buy Rating
Evercore Maintains Caribou Biosciences(CRBU.US) With Hold Rating, Maintains Target Price $3
Caribou Bioscience GAAP EPS of -$0.38 Beats by $0.06, Revenue of $2.02M Misses by $1.07M
Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Lags Revenue Estimates
Caribou Biosciences | 10-Q: Q3 2024 Earnings Report